Skip to main content

Medications for Chronic Myelogenous Leukemia

Other names: Cancer, Chronic Myelogenous Leukemia; Chronic Granulocytic Leukemia; Chronic Myeloid Leukemia; CML; Leukemia, Chronic Granulocytic

Chronic Myelogenous Leukemia is cancer that starts inside bone marrow. Chronic Myelogenous Leukemia causes an uncontrolled growth of immature cells that make a certain type of white blood cell called myeloid cells. The diseased cells build up in the bone marrow and blood.

Drugs used to treat Chronic Myelogenous Leukemia

The medications listed below are related to or used in the treatment of this condition.

Filter
Drug name Rating Reviews Activity ? Rx/OTC Pregnancy CSA Alcohol
Gleevec 8.6 25 reviews for Gleevec to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
imatinib systemic
Drug class:
BCR-ABL tyrosine kinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Tasigna 8.0 30 reviews for Tasigna to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
nilotinib systemic
Drug class:
BCR-ABL tyrosine kinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Sprycel 7.6 18 reviews for Sprycel to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
dasatinib systemic
Drug class:
BCR-ABL tyrosine kinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
imatinib 8.9 32 reviews for imatinib to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
imatinib systemic
Brand name:
Gleevec
Drug class:
BCR-ABL tyrosine kinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
hydroxyurea 9.7 3 reviews for hydroxyurea to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
hydroxyurea systemic
Brand name:
Hydrea
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Bosulif 7.3 6 reviews for Bosulif to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
bosutinib systemic
Drug class:
BCR-ABL tyrosine kinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Hydrea 10 1 review for Hydrea to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
hydroxyurea systemic
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
nilotinib 8.2 39 reviews for nilotinib to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
nilotinib systemic
Brand name:
Tasigna
Drug class:
BCR-ABL tyrosine kinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
dasatinib 7.7 23 reviews for dasatinib to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
dasatinib systemic
Brand names:
Sprycel, Phyrago
Drug class:
BCR-ABL tyrosine kinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Iclusig 5.0 1 review for Iclusig to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
ponatinib systemic
Drug class:
multikinase inhibitors, BCR-ABL tyrosine kinase inhibitors, VEGF/VEGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
anagrelide Off-label Rate Add review
Rx C N
Generic name:
anagrelide systemic
Drug class:
miscellaneous coagulation modifiers
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Off-label:
Yes
bosutinib 7.3 6 reviews for bosutinib to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
bosutinib systemic
Brand name:
Bosulif
Drug class:
BCR-ABL tyrosine kinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
cyclophosphamide 10 2 reviews for cyclophosphamide to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
cyclophosphamide systemic
Drug class:
alkylating agents
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
ponatinib 5.0 1 review for ponatinib to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
ponatinib systemic
Brand name:
Iclusig
Drug class:
multikinase inhibitors, BCR-ABL tyrosine kinase inhibitors, VEGF/VEGFR inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
Myleran 10 1 review for Myleran to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
busulfan systemic
Drug class:
alkylating agents
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Synribo Rate Add review
Rx D N
Generic name:
omacetaxine systemic
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
busulfan 10 1 review for busulfan to treat Chronic Myelogenous Leukemia
Rx D N
Generic name:
busulfan systemic
Brand names:
Myleran, Busulfex
Drug class:
alkylating agents
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Busulfex Rate Add review
Rx D N
Generic name:
busulfan systemic
Drug class:
alkylating agents
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
Scemblix Rate Add review
Rx N
Generic name:
asciminib systemic
Drug class:
BCR-ABL tyrosine kinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
Prescribing Information
asciminib Rate Add review
Rx N
Generic name:
asciminib systemic
Brand name:
Scemblix
Drug class:
BCR-ABL tyrosine kinase inhibitors
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
cytarabine Rate Add review
Rx D N
Generic name:
cytarabine systemic
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
omacetaxine Rate Add review
Rx D N
Generic name:
omacetaxine systemic
Brand name:
Synribo
Drug class:
miscellaneous antineoplastics
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph
fludarabine Off-label Rate Add review
Rx D N
Generic name:
fludarabine systemic
Drug class:
antimetabolites
For consumers:
dosage, interactions, side effects
For professionals:
AHFS DI Monograph, Prescribing Information
Off-label:
Yes
peginterferon alfa-2b Rate Add review
Rx C N
Generic name:
peginterferon alfa-2b systemic
Drug class:
antineoplastic interferons, antiviral interferons
For consumers:
dosage, interactions, side effects
Phyrago Rate Add review
Rx D N
Generic name:
dasatinib systemic
Drug class:
BCR-ABL tyrosine kinase inhibitors
For consumers:
dosage, interactions, side effects

Frequently asked questions

View more FAQ

Learn more about Chronic Myelogenous Leukemia

Care guides

Legend

Rating For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).
Activity Activity is based on recent site visitor activity relative to other medications in the list.
Rx Prescription only.
OTC Over-the-counter.
Rx/OTC Prescription or Over-the-counter.
Off-label This medication may not be approved by the FDA for the treatment of this condition.
EUA An Emergency Use Authorization (EUA) allows the FDA to authorize unapproved medical products or unapproved uses of approved medical products to be used in a declared public health emergency when there are no adequate, approved, and available alternatives.
Expanded Access Expanded Access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.
Pregnancy Category
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act (CSA) Schedule
M The drug has multiple schedules. The schedule may depend on the exact dosage form or strength of the medication.
U CSA Schedule is unknown.
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.
Alcohol
X Interacts with Alcohol.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.